Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03935984 · ClinicalTrials.gov registry record · Phase 4

Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity

A Phase 4 study of Primary Hyperparathyroidism and Hypercalcemia, sponsored by Joseph Sferra.

Recruiting
Registry status
Phase 4
Development phase
37
Enrollment target
1
Study location

NCT03935984 is a Phase 4 study of Primary Hyperparathyroidism and Hypercalcemia that is actively recruiting participants, run by Joseph Sferra. The registered enrollment target is 37 participants, below the 747-participant average among 7 other Primary Hyperparathyroidism trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03935984, a Phase 4 study of Primary Hyperparathyroidism and Hypercalcemia, is actively recruiting participants, sponsored by Joseph Sferra.

RECRUITING
Registry status
Phase 4
Development phase
37 participants
Enrollment target
1
Study location

Study Summary

Patients with biochemically confirmed primary hyperparathyroidism and non-localizing SPECT-CT exam within the past year will be included. Subjects will be treated with calcitonin to lower calcium levels immediately prior to reimaging. The goal of this study is to determine whether lowering calcium will improve uptake/retention of sestamibi and improve sensitivity of SPECT-CT to localize parathyroid adenoma.

Conditions Studied

Primary Hyperparathyroidism Hypercalcemia

Interventions

  • DRUG Calcitonin

Study Locations (1)

Ohio

  • ProMedica Toledo Hospital - Toledo

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2019-05-29
Est. Completion 2026-12-31
Phase Phase 4

Sponsor

Joseph Sferra

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03935984

The ClinicalTrials.gov registry entry for NCT03935984 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 747-participant average among 7 other Primary Hyperparathyroidism trials with a reported enrollment target (95% lower). The listed sponsor is Joseph Sferra, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Primary Hyperparathyroidism appearing as the primary indexed condition, and to 1 intervention - of which Calcitonin is the first listed.

NCT03935984 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT03935984 about?

NCT03935984 is a clinical study titled "Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity". Patients with biochemically confirmed primary hyperparathyroidism and non-localizing SPECT-CT exam within the past year will be included. Subjects will be treated with calcitonin to lower calcium levels immediately prior to reimaging. The goal of this study is to determine whether lowering calcium w...

What is the current status of trial NCT03935984?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 37 participants. The study started on 2019-05-29. Estimated completion is 2026-12-31.

What conditions does trial NCT03935984 study?

This clinical trial studies the following conditions: Primary Hyperparathyroidism, Hypercalcemia.

What interventions are being tested in trial NCT03935984?

The interventions under investigation include: Calcitonin (DRUG).

Who is sponsoring clinical trial NCT03935984?

This trial is sponsored by Joseph Sferra, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03935984 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Primary Hyperparathyroidism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Primary Hyperparathyroidism

All registered trials for this condition

Hypercalcemia

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.